ULBI · Ultralife Corporation

Ultralife’s Q1 FY2026 results reflect a sharp earnings contraction driven by both top-line pressure and margin erosion. Revenue declined 6.5% year-over-year to $47.4 million, with the Communications Systems segment falling 25.7% to $3.3 million—primarily due to delayed orders—while Battery & Energy Products slipped 4.7% to $44.2 million, weighed down by lower oil & gas and industrial commercial sales and a 2.7% dip in government/defense revenue following a large allied-country shipment in Q1 FY2025. Gross margin compressed 380 bps to 21.3%, attributed explicitly to adverse product mix, elevated utility costs, and production inefficiencies—including lost days at Newark (power outage) and Raynham (inventory confirmation/integration activities). Operating expenses rose 10.5% to $10.3 million, fueled by a 23.3% increase in new product development spend and $1.7 million in one-time costs: $0.8 million for consulting and litigation related to gross margin improvement and cyber-insurance claims, and $0.8 million for production-related events. Despite the loss, backlog surged to a record $115.1 million—up $4.9 million sequentially and $20.1 million year-over-year—highlighting robust long-sales-cycle demand for new products. Management emphasized that restoring profitability hinges on improving manufacturing efficiency at Newark, ramping new product output, and accelerating Communications Systems order conversion. With no forward guidance disclosed, investors must assess whether the $115M backlog and ongoing cost initiatives can offset persistent execution headwinds and weak near-term order flow.